PredictImmune awarded £100k for biomarker-based IBD test

Prognostic tools developer, PredictImmune, has been awarded £100,000 by Innovate UK for its biomarker-based technology.

The funding was awarded as part of Innovate UK’s ‘Precision medicine technologies: shaping the future’ competition, which is investing up to £5 million into companies developing precision medicine technologies.

The grant will enable PredictImmune to fund a feasibility study into the use of biomarkers to predict patient response to new and existing treatments for inflammatory bowel disease. If successful, the company could begin biomarker stratified clinical trials to discover and develop more effective treatments for immune-mediated diseases.

The study will use PredictSure IBD, the company’s diagnostic test for assessing the risk patients have for IBD relapse. The test is intended to enable the use of more aggressive treatments to be used for patients who are at the greatest risk of aggressive forms of IBD.

Paul Kinnon, CEO, PredictImmune said: “We are delighted to receive support from Innovate UK in the form of this grant. The commercially driven feasibility studies, using our prognostic test for IBD, PredictSure IBD, will identify which patients will benefit from the early use of more aggressive treatments and which treatment they will best respond to. The study takes us a step closer to achieving our goal of personalised medicine in IBD.”